';
Children's Services

RCPA has signed onto a letter to Congressional leaders of the Ways and Means Committee and the Senate Committee on Finance, along with 244 other signatories, outlining the need for parity in addiction and mental health care under Medicare.

As the President’s 2023 Budget and Senate Finance Committee’s bipartisan report has highlighted, Medicare is not subject to the Mental Health Parity and Addiction Equity Act (Parity Act). As a result, Medicare beneficiaries do not have coverage of or access to the full range of mental health and substance use disorder benefits they need, and often lose access to treatment they were receiving prior to becoming eligible for Medicare. Although Congress has eliminated disparate financial requirements for Medicare beneficiaries, Medicare still imposes both quantitative (e.g. 190-day lifetime limitation on psychiatric hospital care) and non-quantitative treatment limitations that would violate the Parity Act. Applying the Parity Act to Medicare Parts A, B, C, and D is the critical next step to make mental health and substance use disorder services available and accessible to the millions of Medicare beneficiaries in need of treatment.

Read the full letter here.

Image by succo from Pixabay

The Pennsylvania Senate today passed HB 1563 and HB 1561, sending the substance use disorder and mental health confidentiality-related bills to Gov. Wolf to sign into law. He is expected to sign both.

Both bills align Pennsylvania’s confidentiality laws with federal confidentiality laws, including 42 CFR and HIPAA. Barring a Gov. Wolf veto of HB 1563, Pennsylvania’s 4 Pa Code 255.5 will be eliminated.

Advocates of improved care coordination and integration have long pointed to 4 Pa Code 255.5 as a barrier, citing the limited amount of information allowed to be shared and the few entities with whom it could be shared, even with patient consent.

0 1497

FDA Safety Advisory (Issued June 28, 2022): Do not use neck floats with babies for water therapy interventions, especially with babies who have developmental delays or special health care needs.

See the full FDA Communication here.

If you have any questions, please contact RCPA Children’s Policy Director Jim Sharp. Please share with those in your networks. Thank you.

The Council on Brain Injury (CoBI) released the following information regarding a free webinar they will be offering through their clinical forum series on brain injury and substance misuse that will feature opioid misuse. The webinar is scheduled for July 12, 2022, from 3:30 pm – 5:00 pm. Details are below.


CoBI Clinical Forum Series presents: Brain Injury and Substance Misuse, Featuring Opioid Misuse: Practical Implications for Brain Injury Providers (A Webinar)
A Presentation and Discussion With Monica Vaccaro
Tuesday, July 12, 2022   |   3:30 pm – 5:00 pm   |   Webinar

Monica Vaccaro is the Director of Programs for the Brain Injury Association of Pennsylvania (BIAPA), providing oversight and direction to multiple programs, including the Brain Injury Resource Line, NeuroResource Facilitation, Brain Injury and Opioids Training, and the BrainSTEPS School Re-Entry Program. In addition to her role with BIAPA, she is a Research Associate at Moss Rehabilitation Research Institute, with a particular interest in interventions for common effects of brain injury, including anger management, depression, and goal setting.

This session is intended for a professional audience. There is no cost to attend. 

Register Here

Questions? Please contact MJ Schmidt.